Form 4: Corcept Therapeutics Director Acquires Shares

Corcept Therapeutics Director James N. Wilson reported the acquisition of 5,000 shares of common stock on April 6, 2026.

Summary

• James N. Wilson, a Director at Corcept Therapeutics Inc., acquired 5,000 shares of common stock on April 6, 2026.
• The transaction was executed at a price of $0.00, indicating it was likely a grant or award.
• Following this transaction, Mr. Wilson beneficially owns 1,097,532 shares of common stock indirectly through various trusts and partnerships, in addition to direct holdings not specified in this transaction.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock acquisition by a director, which is common practice and does not inherently signal significant positive or negative developments.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition of 5,000 shares by a director is a direct investment in the company.

Negatives

• The acquisition price of $0.00 suggests the shares were not purchased on the open market, but rather awarded or granted, which may not represent new capital investment by the director.

Future Outlook

No specific forward-looking statements or guidance are present in this Form 4 filing.

Industry Context

StockSavvy.ai notes that insider transactions, such as this stock acquisition by a director, are closely watched by the market as potential indicators of management's confidence in the company's performance and future prospects within the biotechnology and pharmaceutical sector.

Stakeholder Impact

• Shareholders: May view director stock acquisitions positively as a sign of confidence, though the $0.00 acquisition price limits interpretation as a new capital investment.
• Employees: Indirect impact through potential positive sentiment towards the company's leadership.
• Management: Reinforces existing beneficial ownership structures and reporting obligations.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, Insider Trading, Stock Acquisition, Director, Beneficial Ownership